Development Drug Trials Drugs Genetics 
Pharmaceutical Technology
JUNE 15, 2023
The need for new medical treatments and drugs has never been greater. But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S.
Drug Discovery World
JUNE 20, 2024
Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for MND.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 25, 2022
When cirrhosis complications develop, some will be lucky enough to be listed for a transplant. Obesity, diabetes, and genetics are the primary drivers, and COVID is about to make this exponentially worse. Dozens of companies are working at various stages of drug development. Others are not so fortunate. About the Author.
Drug Discovery World
MAY 21, 2024
Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. These targets, along with many others, are universally deemed as ‘difficult-to-drug’ targets.
Drug Discovery World
NOVEMBER 7, 2022
In 2018, the UK’s department of health announced an NHS Genomic Medicine Service, which allows patients with rare diseases to have their entire genetic code read in the hope of providing a much-needed diagnosis. That said, some people with rare genetic diseases remain without a molecular diagnosis after their genome is analysed. . “We
XTalks
MAY 16, 2023
The exact cause of pulmonary fibrosis is often unknown, and in such cases, it is referred to as idiopathic pulmonary fibrosis (IPF); however, certain factors can contribute to the development of pulmonary fibrosis, including environmental and occupational exposures, certain medications, autoimmune diseases and genetic predisposition.
XTalks
SEPTEMBER 11, 2020
Disease doesn’t discriminate, and researchers understand different populations react differently to drugs. Why, then, are clinical trials so stubbornly homogeneous? Clinical trials, however, don’t reflect that diversity. When trial populations don’t match the broader patient base, the treatments they produce aren’t as effective.
Expert insights. Personalized for you.
130 
Let's personalize your content